Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07158918RecruitingPhase 1/Phase 2
Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Cleveland, OhioAges 18 years+ - NCT05693844RecruitingPhase 1/Phase 2
MSLN CAR T cell therapy for advanced solid tumors
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Beijing, Beijing MunicipalityAges 18–75 - NCT07228247RecruitingPhase 1/Phase 2
Study of HMPL-A251 for advanced HER2-positive cancers
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05978492RecruitingPhase 1
Study of TXN10128 for advanced solid tumors
This trial is testing a new drug, TXN10128, for people with advanced solid tumors that have stopped responding to other treatments. It may be an option if standard treatments haven't worked or aren't suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06541639RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06046742RecruitingPhase 1
IV M1-c6v1 for advanced solid tumors
This trial tests an experimental drug called M1-c6v1 given through an IV for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective.
Kashiwa-shi, ChibaAges 18 years+ - NCT07252479RecruitingPhase 1
Testing a new RAS inhibitor for advanced solid tumors
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Orlando, FloridaAges 18 years+ - NCT05699811RecruitingPhase 1/Phase 2
Test of special immune-support cells for solid tumors
This study tests lab-made mesenchymal stromal cells that release interferon alpha (IFNα) for people with locally advanced or metastatic solid cancers. It’s designed to see if this treatment can help when standard treatments have failed or don’t have guideline options.
BeijingAges 18–75 - NCT07123103RecruitingPhase 1
Study of XB371 for advanced solid tumors
This trial tests a new drug called XB371 for people with advanced solid tumors that have come back or spread. It aims to see if the drug is safe and works against the cancer.
Rogers, ArkansasAges 18 years+ - NCT06468358RecruitingPhase 1/Phase 2
LB1410 and LB4330 for advanced solid tumors
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06800196RecruitingPhase 1
Study of KNT-0916 for advanced solid tumors with FGFR2 changes
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
Guangzhou, GuangdongAges 18–75 - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+ - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
New York, New YorkAges 18 years+ - NCT06658353RecruitingPhase 3
Study of VC004 for advanced solid tumors
This trial tests a new drug called VC004 for people with advanced solid tumors that have spread. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 12 years+ - NCT07441174RecruitingPhase 1/Phase 2
A study of two drugs for KRAS G12D tumors
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06576037RecruitingPhase 1
Study of CBP-1019 with chemo for advanced solid tumors
This trial tests a new drug called CBP-1019 combined with chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have a type of cancer that hasn't gotten better with other therapies.
Houston, TexasAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,356 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.